Inside UnitedHealth's Margin Problem

The scale is almost incomprehensible. Revenue of $447.6 billion makes UnitedHealth the sixth-largest company in the world by revenue — bigger than Apple, bigger than Amazon. The growth from $287 billion in 2021 to $448 billion in 2025 has been driven primarily by Optum's expansion: acquisitions of physician practices, surgery centres, and home health providers have built a vertically integrated healthcare delivery system.

The vertical integration thesis is elegant. UnitedHealthcare insures the patient. Optum Health provides the care. Optum Rx manages the pharmacy benefit. Optum Insight provides the data analytics and revenue cycle management. At each step, UnitedHealth captures a margin. The concern — which regulators share — is that the same company insuring the care is also providing and managing it, creating conflicts of interest that could attract political and regulatory intervention.

We have covered healthcare conglomerates through two major regulatory cycles. The pattern is consistent: vertical integration works brilliantly until it attracts antitrust scrutiny, at which point the regulatory overhang suppresses the multiple for 18-24 months regardless of the fundamental trajectory.

The headline profit margin of 2.7% on $447.6 billion is one of the lowest in the S&P 500 for a non-commodity business. But that is partly structural — health insurance inherently operates on 3-5% margins because most premium revenue flows through to claims. The concern is the direction.

In 2023, the profit margin was 6.0%. In 2024, it dropped to 3.6%. In 2025, it fell further to 2.7%. That is a 330 basis point compression in two years. The medical loss ratio — the percentage of premium revenue paid out in claims — has been creeping higher as healthcare utilisation normalises post-pandemic. Members are using more services, filling more prescriptions, and scheduling more elective procedures.

The operating margin tells an even starker story: 0.34% in 2025, down from a more typical 8-9% range. Something has clearly changed in the operating cost structure. Part of this is the aftermath of the 2024 cyberattack on Change Healthcare, which disrupted claims processing and cost the company billions in remediation. Part of it is genuine medical cost inflation running ahead of premium increases.

EPS of $13.23 is down meaningfully from the $23-25 range investors had grown accustomed to. The consensus target of $357.81 implies 29% upside, which tells you the market expects a margin recovery. The question is how fast it comes.

Optum is the reason to stay engaged with this stock. The services segment has been growing revenue at 15-18% annually, with operating margins in the 6-8% range — modest by tech standards but exceptional by healthcare standards. Optum Health's physician employment model — the company employs or affiliates with over 90,000 physicians — creates a structural advantage in value-based care contracts that no competitor can match at scale.

Optum Rx processes over 1.4 billion prescriptions annually, making it the largest pharmacy benefits manager in the US. The data generated by this volume feeds Optum Insight's analytics platform, which in turn helps UnitedHealthcare price its insurance products more accurately. The flywheel is real and defensible.

Free cash flow of $16.1 billion — down from $20.7 billion in 2024 and $25.7 billion in 2023 — remains substantial. The FCF yield of 6.4% on a $251.7 billion market cap is attractive by any measure. The cash generation capacity is not in question. The margin trajectory is.

UnitedHealth's competitive position is, paradoxically, both its greatest strength and its greatest vulnerability. No competitor — not CVS/Aetna, not Cigna/Express Scripts, not Humana — has replicated the full vertical integration stack. That makes UnitedHealth the most efficient healthcare company in America by a wide margin.

But the efficiency creates the political target. When one company controls insurance, care delivery, pharmacy benefits, and data analytics for 50+ million Americans, the political will to intervene is substantial and bipartisan. The FTC has been scrutinising vertical integration in healthcare, and several state attorneys general have challenged specific Optum acquisitions. We are not building a regulatory breakup scenario into our base case, but we assign it a 10-15% probability over a five-year horizon — enough to justify a 1-2 turn PE discount.

Medicare Advantage enrollment growth is the most visible driver. The over-65 population is growing at 3% annually, and MA penetration continues to increase as seniors choose managed care over traditional fee-for-service Medicare. UnitedHealth is the largest MA insurer, and the demographic tailwind has at least a decade to run.

Optum's expansion into primary care delivery — through acquisitions and organic clinic openings — is the higher-growth, higher-margin opportunity. Value-based care contracts, where the provider is paid for health outcomes rather than service volume, are growing rapidly and Optum's data infrastructure gives it a structural advantage in pricing these contracts profitably.

International expansion is a longer-dated option. UnitedHealth has operations in Brazil and select other markets, but the US healthcare system's unique complexity makes the domestic business the priority for the foreseeable future.